In babies, RSV is a common cause of a type of chest infection called bronchiolitis. Last week, the UK Health Security Agency ...

Secretary Robert F. Kennedy Jr. said his department would slash funding for mRNA vaccine research and shift its focus to ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...

AI has become a critical tool in diagnosing and managing viral infections such as influenza, respiratory syncytial virus (RSV ...

The study found the program was more than 85% effective in reducing infant hospitalizations, emergency-room consultations and ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held ...